Quick Answer
Translational Development Acquisition Corp. reported Stockholders Equity of -$6.54 million for the year ending 2025.
- Translational Development Acquisition Corp. showed a decrease of -16.9% in Stockholders Equity from 2024 to 2025.
- This data is from Translational Development Acquisition Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$507.7 thousand | Q2 2024: -$509.3 thousand | Q3 2024: -$570.6 thousand | Q1 2025: -$5.94 million | Q2 2025: -$6.17 million | Q3 2025: -$6.38 million.
- Over the full 4 years of available data (2022 to 2025), Translational Development Acquisition Corp.'s Stockholders Equity has declined by 29,491.6%.
- Historical annual values: Fiscal year 2025: -$6.54 million | Fiscal year 2024: -$5.60 million | Fiscal year 2023: -$507.7 thousand | Fiscal year 2022: -$22.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: